Skin lesions may hold the key to diagnosing dengue, Zika, chikungunya, and Oropouche fever. Learn how dermatologists can spot ...

FDA granted CORDStrom™ a Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) for treatment of epidermolysis bullosa (EB). Data from the MissionEB trial show that ...

Ligand Pharmaceuticals offers biotech exposure with reduced risk through its royalty platform. Discover why its valuation now ...

Dr. Mark Liddell invented and perfected CORDStrom to support an NIHR-funded trial in the UK treating kids with intermediate to severe recessive dystrophic epidermolysis bullosa or RDEB.

With several pediatric-focused therapies advancing through late ... to treat recessive dystrophic epidermolysis bullosa (RDEB). Based on data from the phase 3 VITAL study and a phase 1/2a study with ...

Following Elliana's diagnosis, the family moved from Virginia to Maine in order to live near family as well as be in closer proximity to the pediatric care specialists ... Junctional Epidermolysis ...

She has served as the lead investigator for more than 100 clinical trials in the pediatric dermatology space. Her main areas of expertise include genetic skin disorders such as epidermolysis bullosa ...

Meanwhile, the topical formulation has also recently received orphan drug designation for epidermolysis bullosa, as well as rare pediatric disease designation for primary CoQ10 deficiency. In October ...

Trailer: Pearl Jam frontman Eddie Vedder's new documentary, 'Matter of Time, ' raises awareness and funds for epidermolysis ...